Brain regional α-[11C]methyl-L-tryptophan trapping in medication-free patients with obsessive-compulsive disorder

Archives of General Psychiatry

Volumn 68, Issue 7, 2011, Pages 732-741

  Berney, Alexandre ^a,b,f   Leyton, Marco ^a,b   Gravel, Paul ^a,b   Sibon, Igor ^a,b,g   Sookman, Debbie ^a,c   Rosa Neto, Pedro ^a,b   Diksic, Mirko ^b   Nakai, Akio ^b,h   Pinard, Gilbert ^a   Todorov, Christo ^d   Okazawa, Hidehiko ^b,h   Blier, Pierre ^a,i   Nordahl, Thomas Edward ^e   Benkelfat, Chawki ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h UNIVERSITY OF FUKUI   (Japan)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; N METHYLTRYPTOPHAN; N METHYLTRYPTOPHAN C 11; SEROTONIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIPPOCAMPUS; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; POSITRON EMISSION TOMOGRAPHY; SYMPTOM; TEMPORAL GYRUS;

ADOLESCENT; ADULT; BRAIN; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; FEMALE; HIPPOCAMPUS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; POSITRON-EMISSION TOMOGRAPHY; TEMPORAL LOBE; TRYPTOPHAN; YOUNG ADULT;

EID: 79960302921     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archgenpsychiatry.2011.16     Document Type: Article

References (124)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
2. Aouizerate B, Guehl D, Cuny E, Rougier A, Bioulac B, Tignol J, Burbaud P. Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol. 2004;72(3):195-221. (Pubitemid 38591296)
3. Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-triatal model revisited. Neurosci Biobehav Rev. 2008;32(3):525-549. (Pubitemid 351173336)
4. Mallet L, Polosan M, Jaafari N, Baup N, Welter ML, Fontaine D, du Montcel ST, Yelnik J, Chéreau I, Arbus C, Raoul S, Aouizerate B, Damier P, Chabardès S, Czernecki V, Ardouin C, Krebs MO, Bardinet E, Chaynes P, Burbaud P, Cornu P, Derost P, Bougerol T, Bataille B, Mattei V, Dormont D, Devaux B, Vérin M, Houeto JL, Pollak P, Benabid AL, Agid Y, Krack P, Millet B, Pelissolo A; STOC Study Group. Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med. 2008;359(20):2121-2134.
5. Rotge JY, Guehl D, Dilharreguy B, Cuny E, Tignol J, Bioulac B, Allard M, Burbaud P, Aouizerate B. Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci. 2008;33(5):405-412.
6. McDonough M, Kennedy N. Pharmacological management of obsessive-compulsive disorder: a review for clinicians. Harv Rev Psychiatry. 2002; 10(3):127-137. (Pubitemid 34553137)
7. Zohar J, Insel TR. Drug treatment of obsessive-compulsive disorder. J Affect Disord. 1987;13(2):193-202. (Pubitemid 17156187)
8. Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull. 1990;26(3):279-284. (Pubitemid 20386896)
9. Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry. 1989;46(1):23-28. (Pubitemid 19038404)
10. Greenberg BD, Benjamin J, Martin JD, Keuler D, Huang SJ, Altemus M, Murphy DL. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology (Berl). 1998;140(4):434-444. (Pubitemid 28566842)
11. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL. Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Arch Gen Psychiatry. 1987;44(11):946-951. (Pubitemid 18009649)
12. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR. Serotonergic function in obsessive-compulsive disorder: behavioral and neuroendocrine responses to oralm- chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry. 1992;49(1):21-28.
13. Pigott TA, Zohar J, Hill JL, Bernstein SE, Grover GN, Zohar-Kadouch RC, Murphy DL. Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;29(5):418-426.
14. Khanna S, John JP, Reddy LP. Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder. Psychoneuroendocrinology. 2001; 26(2):209-223.
15. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2001;11(2):169-172. (Pubitemid 32335559)
16. Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology. 2004;50 (3):200-205. (Pubitemid 39279410)
17. Aouizerate B, Guehl D, Cuny E, Rougier A, Burbaud P, Tignol J, Bioulac B. Updated overview of the putative role of the serotoninergic system in obsessive-compulsive disorder. Neuropsychiatr Dis Treat. 2005;1(3):231-243.
18. Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, Charney DS, Heninger GR. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry. 1995;38(3):138-149.
19. Ho Pian KL, Westenberg HG, den Boer JA, de Bruin WI, van Rijk PP. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls. Biol Psychiatry. 1998;44(5):367-370.
20. Boshuisen ML, den Boer JA. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology (Berl). 2000;152(1):74-79.
21. Hollander E, Stein DJ, Saoud JB, DeCaria CM, Cooper TB, Trungold S, Stanley M, Liebowitz MR. Effects of fenfluramine on plasma HVA in OCD. Psychiatry Res. 1992;42(2):185-188.
22. Charney DS, Goodman WK, Price LH, Woods SW, Rasmussen SA, Heninger GR. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan andm-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988;45(2):177-185. (Pubitemid 18052850)
23. Smeraldi E, Diaferia G, Erzegovesi S, Lucca A, Bellodi L, Moja EA. Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry. 1996;40(5): 398-402. (Pubitemid 26301071)
24. Berney A, Sookman D, Leyton M, Young SN, Benkelfat C. Lack of effects on core obsessive-compulsive symptoms of tryptophan depletion during symptom provocation in remitted obsessive-compulsive disorder patients. Biol Psychiatry. 2006;59(9):853-857.
25. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry. 1985; 20(11):1174-1188. (Pubitemid 16053592)
26. Swedo SE, Leonard HL, Kruesi MJ, Rettew DC, Listwak SJ, Berrettini W, Stipetic M, Hamburger S, Gold PW, Potter WZ, Rapoport JL. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49(1):29-36.
27. Altemus M, Pigott T, Kalogeras KT, Demitrack M, Dubbert B, Murphy DL, Gold PW. Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder. Arch Gen Psychiatry. 1992; 49(1):9-20.
28. Leckman JF, Goodman WK, Anderson GM, Riddle MA, Chappell PB, McSwiggan-Hardin MT, McDougle CJ, Scahill LD, Ort SI, Pauls DL, Cohen DJ, Price LH. Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology. 1995;12(1): 73-86.
29. Pogarell O, Hamann C, Pöpperl G, Juckel G, Choukèr M, Zaudig M, Riedel M, Möller HJ, Hegerl U, Tatsch K. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry. 2003;54 (12):1406-1413. (Pubitemid 37522165)
30. Stengler-Wenzke K, Müller U, Angermeyer MC, Sabri O, Hesse S. Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD). Eur Arch Psychiatry Clin Neurosci. 2004;254(4):252-255. (Pubitemid 39312840)
31. Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. Psychiatry Res. 2005;140(1):63-72. (Pubitemid 41443497)
32. Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, Mundt A, Smoltczyk HU, Goldman D, Mann K, Reischl G, Machulla HJ, Bares R, Heinz A. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity: a [11C]DASB PET study. J Neural Transm. 2007;114(12):1603-1609. (Pubitemid 350212008)
33. Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Schmidl- Mohl B, Wenzel T, Demal U, Zettinig G, Hornik K, Thau K. [123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers. Neuropsychopharmacology. 2007;32(8):1661-1668. (Pubitemid 47076373)
34. Simpson HB, Lombardo I, Slifstein M, Huang HY, Hwang DR, Abi-Dargham A, Liebowitz MR, Laruelle M. Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry. 2003;54(12):1414-1421. (Pubitemid 37522166)
35. van der Wee NJ, Stevens H, Hardeman JA, Mandl RC, Denys DA, van Megen HJ, Kahn RS, Westenberg HM. Enhanced dopamine transporter density in psychotropic naive patients with obsessive-compulsive disorder shown by [123I]beta-CITSPECT. Am J Psychiatry. 2004;161(12):2201-2206. (Pubitemid 39587284)
36. Bloch MH, Landeros-Weisenberger A, Sen S, Dombrowski P, Kelmendi B, Coric V, Pittenger C, Leckman JF. Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):850-858.
37. El Mansari M, Blier P. Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(3):362-373. (Pubitemid 43841738)
38. Munafò MR, Brown SM, Hariri AR. Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis. Biol Psychiatry. 2008;63 (9):852-857. (Pubitemid 351458448)
39. New AS, Hazlett EA, Buchsbaum MS, Goodman M, Mitelman SA, Newmark R, Trisdorfer R, Haznedar MM, Koenigsberg HW, Flory J, Siever LJ. Amygdala-prefrontal disconnection in borderline personality disorder. Neuropsychopharmacology.2007; 32(7):1629-1640. (Pubitemid 46920160)
40. Leyton M, Paquette V, Gravel P, Rosa-Neto P, Weston F, Diksic M, Benkelfat C. alpha-[11C]Methyl-L-tryptophan trapping in the orbital and ventral medial prefrontal cortex of suicide attempters. Eur Neuropsychopharmacol. 2006;16 (3):220-223. (Pubitemid 43358012)
41. Diksic M, Young SN. Study of the brain serotonergic system with labeled alpha-methyl-L-tryptophan. J Neurochem. 2001;78(6):1185-1200. (Pubitemid 32899751)
42. Chugani DC, Muzik O. Alpha[C-11]methyl-L-tryptophan PET maps brain serotonin synthesis and kynurenine pathway metabolism. J Cereb Blood Flow Metab. 2000;20(1):2-9. (Pubitemid 30019823)
43. Diksic M, Nagahiro S, Sourkes TL, Yamamoto YL. A new method to measure brain serotonin synthesis in vivo: I, theory and basic data for a biological model. J Cereb Blood Flow Metab. 1990;10(1):1-12. (Pubitemid 20035849)
44. Diksic M, Nagahiro S, Chaly T, Sourkes TL, Yamamoto YL, Feindel W. Serotonin synthesis rate measured in living dog brain by positron emission tomography. J Neurochem. 1991;56(1):153-162. (Pubitemid 21901943)
45. Nishizawa S, Benkelfat C, Young SN, Leyton M, Mzengeza S, de Montigny C, Blier P, Diksic M. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A. 1997;94(10):5308-5313. (Pubitemid 27214779)
46. Chugani DC, Muzik O, Rothermel R, Behen M, Chakraborty P, Mangner T, da Silva EA, Chugani HT. Altered serotonin synthesis in the dentatothalamocortical pathway in autistic boys. Ann Neurol. 1997;42(4):666-669. (Pubitemid 27439032)
47. Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT.Humanbrain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L- tryptophan. Synapse. 1998;28(1):33-43. (Pubitemid 128770601)
48. Okazawa H, Leyton M, Benkelfat C, Mzengeza S, Diksic M. Statistical mapping analysis of serotonin synthesis images generated in healthy volunteers using positron-emission tomography and alpha-[11C]methyl-L-tryptophan. J Psychiatry Neurosci. 2000;25(4):359-370.
49. Leyton M, Okazawa H, Diksic M, Paris J, Rosa P, Mzengeza S, Young SN, Blier P, Benkelfat C. Brain Regional alpha-[11C]methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry. 2001; 158(5):775-782. (Pubitemid 32429847)
50. Chugani DC, Niimura K, Chaturvedi S, Muzik O, Fakhouri M, Lee ML, Chugani HT. Increased brain serotonin synthesis in migraine. Neurology. 1999;53 (7):1473-1479. (Pubitemid 29491940)
51. Chugani DC, Muzik O, Behen M, Rothermel R, Janisse JJ, Lee J, Chugani HT. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol. 1999;45(3):287-295. (Pubitemid 29120032)
52. Pfund Z, Chugani DC, Muzik O, Juhász C, Behen ME, Lee J, Chakraborty P, Mangner T, Chugani HT. Alpha[11C] methyl-L-typtophan positron emission tomography in patients with alternating hemiplegia of childhood. J Child Neurol. 2002; 17(4):253-260. (Pubitemid 34823420)
53. Rosa-Neto P, Diksic M, Okazawa H, Leyton M, Ghadirian N, Mzengeza S, Nakai A, Debonnel G, Blier P, Benkelfat C. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry. 2004;61 (6):556-563. (Pubitemid 38747310)
54. Baxter LR Jr, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH, Fairbanks L. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. Am J Psychiatry. 1988;145(12):1560-1563. (Pubitemid 19009706)
55. Nordahl TE, Benkelfat C, Semple WE, Gross M, King AC, Cohen RM. Cerebral glucosemetabolicratesinobsessivecompulsivedisorder. Neuropsychopharmacology. 1989;2(1):23-28.
56. Sawle GV, Hymas NF, Lees AJ, Frackowiak RS. Obsessional slowness: functional studies with positron emission tomography. Brain. 1991;114(pt 5): 2191-2202.
57. Perani D, Colombo C, Bressi S, Bonfanti A, Grassi F, Scarone S, Bellodi L, Smeraldi E, Fazio F. [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment. Br J Psychiatry. 1995;166(2):244-250.
58. Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, Baxter LR Jr. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry. 2001;50(3):159-170. (Pubitemid 32763093)
59. Benkelfat C, Nordahl TE, Semple WE, King AC, Murphy DL, Cohen RM. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine. Arch Gen Psychiatry. 1990;47(9):840-848. (Pubitemid 20302699)
60. Baxter LR Jr. Neuroimaging studies of obsessive compulsive disorder. Psychiatr Clin North Am. 1992;15(4):871-884.
61. Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder: revisualization during pharmacotherapy. Arch Gen Psychiatry. 1992;49(9):690-694.
62. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, Baxter LR Jr. Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry. 2002;59(3):250-261. (Pubitemid 34212502)
63. Schwartz JM, Stoessel PW, Baxter LR Jr, Martin KM, Phelps ME. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1996; 53(2):109-113. (Pubitemid 26049387)
64. First M, Spitzer R, Gibbon M, Williams JB. Structured Clinical Interview for the DSM-IV Axis I Disorders (SCID I/P, Version 2.0). New York, NY: Biometrics Research Dept, New York State Psychiatric Institute; 1995.
65. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale: I, development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. (Pubitemid 19278229)
66. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
67. Mzengeza S, Venkatachalam TK, Diksic M. Asymmetric radiosynthesis of alpha-[11C]methyl-L-tryptophan for PET studies. Nucl Med Biol. 1995;22(3):303-307.
68. Nishizawa S, Leyton M, Okazawa H, Benkelfat C, Mzengeza S, Diksic M. Validation of a less-invasive method for measurement of serotonin synthesis rate with alpha-[11C]methyl-tryptophan. J Cereb Blood Flow Metab. 1998;18 (10):1121-1129. (Pubitemid 28465360)
69. Gharib A, Balende C, Sarda N, Weissmann D, Plenevaux A, Luxen A, Bobillier P, Pujol JF. Biochemical and autoradiographic measurements of brain serotonin synthesis rate in the freely moving rat: a reexamination of the alpha-methyl-L-tryptophan method. J Neurochem. 1999;72(6):2593-2600. (Pubitemid 29242212)
70. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-tobrain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1-7. (Pubitemid 13129630)
71. Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18(2):192-205. (Pubitemid 24100002)
72. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998; 17(1):87-97. (Pubitemid 128742012)
73. Zijdenbos A, Forghani R, Evans A. Automatic quantification of MS lesions in 3D MRI brain data sets: validation of INSECT. In: Wells WM, Colchester A, Delp S, eds. Medical Image Computing and Computer-Assisted Intervention: MICCAI' 98: First International Conference, Cambridge, MA, USA, October 11-13, 1998, Proceedings (Lecture Notes in Computer Science). New York, NY: Springer-Verlag;1998:439-448.
74. Collins DL, Zijdenbos AP, Baare WFC, Evans AC. ANIMAL+INSECT: improved cortical structure segmentation. In: Kuba A, Samal M, Todd-Pokropek A, eds. Information Processing in Medical Imaging: 16th International Conference, IPMI'99, Visegrad, Hungary, June 28-July 2, 1999, Proceedings (Lecture Notes in Computer Science). New York, NY: Springer-Verlag;1999:210-223.
75. MacDonnald D. Program for Display and Segmentation of Surfaces and Volumes. Montreal, Quebec: McConell Brain Imaging Centre, Montreal Neurological Institute; 1996.
76. Lieberman J. Evidence for a biological hypothesis of obsessive-compulsive disorder. Neuropsychobiology. 1984;11(1):14-21. (Pubitemid 14106133)
77. Chamberlain SR, Fineberg NA, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. A neuropsychological comparison of obsessive-compulsive disorder and trichotillomania. Neuropsychologia. 2007;45(4):654-662. (Pubitemid 46001411)
78. Di Cara B, Samuel D, Salin P, Kerkerian-Le Goff L, Daszuta A. Serotonergic regulation of the GABAergic transmission in the rat basal ganglia. Synapse. 2003; 50(2):144-150. (Pubitemid 37152148)
79. Anguiano-Rodr?́guez PB, Gaytán-Tocavén L, Olvera-Cortés ME. Striatal serotonin depletion facilitates rat egocentric learning via dopamine modulation. Eur J Pharmacol. 2007;556(1-3):91-98. (Pubitemid 46073993)
80. Insel TR. Toward a neuroanatomy of obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49(9):739-744.
81. Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage. 2008;42(1):306-314.
82. Rueter LE, Tecott LH, Blier P. In vivo electrophysiological examination of 5-HT2 responses in 5-HT2C receptor mutant mice. Naunyn Schmiedebergs Arch Pharmacol. 2000;361(5):484-491. (Pubitemid 30262596)
83. Turner DA, Buhl EH, Hailer NP, Nitsch R. Morphological features of the entorhinal-hippocampal connection. Prog Neurobiol. 1998;55(6):537-562. (Pubitemid 28293580)
84. Paus T, Zijdenbos A, Worsley K, Collins DL, Blumenthal J, Giedd JN, Rapoport JL, Evans AC. Structural maturation of neural pathways in children and adolescents: in vivo study. Science. 1999;283(5409):1908-1911.
85. White NM, Salinas JA. Mnemonic functions of dorsal striatum and hippocampus in aversive conditioning. Behav Brain Res. 2003;142(1-2):99-107. (Pubitemid 36677595)
86. Packard MG, Teather LA. Amygdala modulation of multiple memory systems: hippocampus and caudate-putamen. Neurobiol Learn Mem. 1998;69(2): 163-203. (Pubitemid 28364515)
87. Packard MG, Cahill L. Affective modulation of multiple memory systems. Curr Opin Neurobiol. 2001;11(6):752-756. (Pubitemid 34014927)
88. Depue RA, Spoont MR. Conceptualizing a serotonin trait: a behavioral dimension of constraint. Ann N Y Acad Sci. 1986;487:47-62.
89. Gray JA, McNaughton N. The Neuropsychology of Anxiety: An Inquiry Into the Functions of the Septo-Hippocampal System (Oxford Psychology Series). New York, NY: Oxford University Press; 2000.
90. McNaughton N, Wickens J. Hebb, pandemonium and catastrophic hypermnesia: the hippocampus as a suppressor of inappropriate associations. Cortex. 2003;39(4-5):1139-1163. (Pubitemid 37351086)
91. Radomsky AS, Rachman S, Hammond D. Memory bias, confidence and responsibility in compulsive checking. Behav Res Ther. 2001;39(7):813-822. (Pubitemid 32510709)
92. van den Hout M, Kindt M. Obsessive-compulsive disorder and the paradoxical effects of perseverative behaviour on experienced uncertainty. J Behav Ther Exp Psychiatry. 2004;35(2):165-181. (Pubitemid 38822907)
93. Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci. 2007; 30(5):220-227. (Pubitemid 46654234)
94. Goto Y, Grace AA. Dopamine modulation of hippocampal-prefrontal cortical interaction drives memory-guided behavior. Cereb Cortex. 2008;18(6):1407-1414. (Pubitemid 351769794)
95. Hollander E, ed. Obsessive-Compulsive Related Disorders. Washington, DC: American Psychiatric Publishing, Inc; 1993.
96. Shoaf SE, Carson RE, Hommer D, Williams WA, Higley JD, Schmall B, Herscovitch P, Eckelman WC, Linnoila M. The suitability of [11C]-alpha-methyl-L- tryptophan as a tracer for serotonin synthesis: studies with dual administration of [11C] and [14C] labeled tracer. J Cereb Blood Flow Metab. 2000; 20(2):244-252.
97. Diksic M, Tohyama Y, Takada A. Brain net unidirectional uptake of alpha-[14c]methyl-L-tryptophan (alpha-MTrp) and its correlation with regional serotonin synthesis, tryptophan incorporation into proteins, and permeability surface area products of tryptophan and alpha-MTrp. Neurochem Res. 2000; 25(12):1537-1546.
98. Nishikawa M, Kumakura Y, Young SN, Fiset P, Vogelzangs N, Leyton M, Benkelfat C, Diksic M. Increasing blood oxygen increases an index of 5-HT synthesis in human brain as measured using alpha-[(11)C]methyl-L-tryptophan and positron emission tomography. Neurochem Int. 2005;47(8):556-564. (Pubitemid 41437900)
99. Tohyama Y, Takahashi S, Merid MF, Watanabe A, Diksic M. The inhibition of tryptophan hydroxylase, not protein synthesis, reduces the brain trapping of alpha-methyl-L-tryptophan: an autoradiographic study. Neurochem Int. 2002; 40(7):603-610.
100. Hasegawa S, Kanemaru K, Gittos M, Diksic M. The tryptophan hydroxylase activation inhibitor, AGN-2979, decreases regional 5-HT synthesis in the rat brain measured with alpha-[14C]methyl-L-tryptophan: an autoradiographic study. Brain Res Bull. 2005;67(3):248-255. (Pubitemid 41242931)
101. Muzik O, Chugani DC, Chakraborty P, Mangner T, Chugani HT. Analysis of [C-11]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate in vivo. J Cereb Blood Flow Metab. 1997;17(6):659-669. (Pubitemid 27306690)
102. Chugani DC, Chugani HT. PET: mapping of serotonin synthesis. Adv Neurol. 2000;83:165-171.
103. Leyton M, Diksic M, Benkelfat C. Brain regional alpha-[11C]methyl-L- tryptophan trapping correlates with post-mortem tissue serotonin content and [11C]5-hydroxytryptophan accumulation. Int J Neuropsychopharmacol. 2005; 8(4):633-634. (Pubitemid 41400895)
104. Lundquist P, Hartvig P, Blomquist G, Hammarlund-Udenaes M, Långström B. 5-Hydroxy-L-[beta-11C]tryptophan versus alpha-[11C]methyl-L-tryptophan for positron emission tomography imaging of serotonin synthesis capacity in the rhesus monkey brain. J Cereb Blood Flow Metab. 2007;27(4):821-830. (Pubitemid 46474613)
105. Booij L, Van der Does W, Benkelfat C, Bremner JD, Cowen PJ, Fava M, Gillin C, Leyton M, Moore P, Smith KA, Van der Kloot WA. Predictors of mood response to acute tryptophan depletion: a reanalysis. Neuropsychopharmacology. 2002;27(5):852-861. (Pubitemid 35335901)
106. Delgado PL, Charney DS, Price LH, Aghajanian GK, Landis H, Heninger GR. Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 1990;47(5):411-418. (Pubitemid 20161259)
107. Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry. 1989;46(3):243-250. (Pubitemid 19078261)
108. Soares JC, Mann JJ. The functional neuroanatomy of mood disorders. J Psychiatr Res. 1997;31(4):393-432. (Pubitemid 27412315)
109. Mataix-Cols D, Rosario-Campos MC, Leckman JF. A multidimensional model of obsessive-compulsive disorder. Am J Psychiatry. 2005;162(2):228-238. (Pubitemid 40216199)
110. Bloch MH, Landeros-Weisenberger A, Rosario MC, Pittenger C, Leckman JF. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry. 2008;165(12):1532-1542.
111. Drevets WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol. 2001;11(2):240-249. (Pubitemid 32289413)
112. Adams KH, Hansen ES, Pinborg LH, Hasselbalch SG, Svarer C, Holm S, Bolwig TG, Knudsen GM. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol. 2005;8(3):391-401. (Pubitemid 41002493)
113. Heyes MP, Saito K, Major EO, Milstien S, Markey SP, Vickers JH. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease: attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain. 1993;116(pt 6):1425-1450. (Pubitemid 24038860)
114. Juhász C, Chugani DC, Muzik O, Shah A, Asano E, Mangner TJ, Chakraborty PK, Sood S, Chugani HT. Alpha-methyl-L-tryptophan PET detects epileptogenic cortex in children with intractable epilepsy. Neurology. 2003;60(6): 960-968. (Pubitemid 36348928)
115. Juhász C, Chugani DC, Muzik O, Wu D, Sloan AE, Barger G, Watson C, Shah AK, Sood S, Ergun EL, Mangner TJ, Chakraborty PK, Kupsky WJ, Chugani HT. In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan inhumanbrain tumors. J Cereb Blood Flow Metab. 2006;26(3):345-357.
116. Snider LA, Swedo SE. PANDAS: current status and directions for research. Mol Psychiatry. 2004;9(10):900-907. (Pubitemid 39381954)
117. Saporta AS, Chugani HT, Juhász C, Makki MI, Muzik O, Wilson BJ, Behen ME. Multimodality neuroimaging in Tourette syndrome: alpha-[11C] methyl-L-tryptophan positron emission tomography and diffusion tensor imaging studies. J Child Neurol. 2010;25(3):336-342.
118. Kim JJ, Lee MC, Kim J, Kim IY, Kim SI, Han MH, Chang KH, Kwon JS. Grey matter abnormalities in obsessive-compulsive disorder: statistical parametric mapping of segmented magnetic resonance images. Br J Psychiatry. 2001; 179:330-334. (Pubitemid 32996042)
119. Pujol J, Soriano-Mas C, Alonso P, Cardoner N, Menchón JM, Deus J, Vallejo J. Mapping structural brain alterations in obsessive-compulsive disorder. Arch Gen Psychiatry. 2004;61(7):720-730. (Pubitemid 38890807)
120. Robinson D, Wu H, Munne RA, Ashtari M, Alvir JM, Lerner G, Koreen A, Cole K, Bogerts B. Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52(5):393-398.
121. Aylward EH, Harris GJ, Hoehn-Saric R, Barta PE, Machlin SR, Pearlson GD. Normal caudate nucleus in obsessive-compulsive disorder assessed by quantitative neuroimaging. Arch Gen Psychiatry. 1996;53(7):577-584. (Pubitemid 26240860)
122. Rotge JY, Langbour N, Guehl D, Bioulac B, Jaafari N, Allard M, Aouizerate B, Burbaud P. Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation meta-analysis. Neuropsychopharmacology. 2010; 35(3):686-691.
123. Rotge JY, Guehl D, Dilharreguy B, Tignol J, Bioulac B, Allard M, Burbaud P, Aouizerate B. Meta-analysis of brain volume changes in obsessive-compulsive disorder. Biol Psychiatry. 2009;65(1):75-83.
124. Radua J, van den Heuvel OA, Surguladze S, Mataix-Cols D. Meta-analytical comparison of voxel-based morphometry studies in obsessive-compulsive disorder vs other anxiety disorders. Arch Gen Psychiatry. 2010;67(7):701-711.